Combining EGFR TKIs with VEGF pathway inhibitors is promising for EGFR-mutant NSCLC, as EGFR activation promotes VEGF expression via overlapping signaling pathways [264]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.